GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

GSK shares sink after FDA panel rejects Blenrep cancer drug, raising doubts over turnaround strategy. GSK (LSE: GSK) investors took a sharp knock on Friday after its much-hyped blood cancer drug, ...

A setback for GSK after one of its late-stage pipeline assets failed to win the support of a US panel today triggered a 6% ...

The FDA has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled syringe presentation to prevent shingles.

Investing.com -- GSK (LON: GSK) shares dropped more than 6% on Friday after a U.S. Food and Drug Administration advisory panel voted against the benefit-risk profile of Blenrep (belantamab ...

GSK was the standout laggard on the FTSE 100, sinking 6.2% after a US Food & Drug Administration advisory panel voted against approving its cancer drug Blenrep at the proposed dosage. Although the FDA ...

(Alliance News) - Stock prices in Europe opened higher early on Friday, with the FTSE 100 almost hitting a new record high, as a swathe of dealmaking was well-received in London. The FTSE 100 index ...

According to reports, the USFDA's Oncologic Advisory Committee voted that the risks from the drug, called Blenrep, outweighed ...

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

London stocks rose in early trade on Friday, taking their cue from a positive close on Wall Street, where the S&P 500 and ...

3M reports second-quarter earnings on Friday. Wall Street is looking for earnings per share of $2.01 from sales of $6.1 billion. In the wake of the offer being withdrawn Wednesday, analysts expect a ...